


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-1.66%
+0.84%
+1.28%
-0.09%
SNDX
Syndax Pharmaceutica
$16.62
Strengths

Earnings are forecast to grow

Trading below its fair value
Chart
$15.57 (+6.74%)
$16.24 (+2.34%)
$9.3 (+78.71%)
$16.72 (-0.60%)
SNDX has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

SNDX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
SNDX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SNDX Street Sentiment is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is SNDX current stock price?
What are SNDX stock strengths?
What is SNDX Risk Level?
What is SNDX market cap and volume?
What is SNDX current Stock IQ?
Should I buy SNDX stock right now?
Is SNDX a Strong Buy right now?
What does a 'Strong Buy' rating mean for SNDX?
What does a 'Strong Sell' rating mean for SNDX?
What factors influence SNDX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-1.66%
+0.84%
+1.28%
-0.09%
SNDX
Syndax Pharmaceutica
Current Price
$16.62
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value

Chart
$15.57 (+6.74%)
$16.24 (+2.34%)
$9.3 (+78.71%)
$16.72 (-0.60%)
SNDX Analysts Opinion
SNDX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
SNDX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SNDX Street Sentiment is bullish and have positive views on the near-term outlook
SNDX has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels.
SNDX Latest Analysis
JP Morgan Maintains Syndax Pharmaceuticals (SNDX) Overweight Recommendation. Fintel reports that on November 12 2025 JP Morgan maintained coverage of Syndax Pharmaceuticals (NasdaqGS:SNDX) with a Overweight recommendation. Analyst Price Forecast Suggests 131.73% Upside
Thu Nov 13, 2025
Syndax Pharmaceuticals Stock Earns RS Rating Upgrade. A Relative Strength Rating upgrade for Syndax Pharmaceuticals shows improving technical performance. Will it continue?The post Syndax Pharmaceuticals Stock Earns RS Rating Upgrade appeared first on Investor'.s Business Daily.
Tue Nov 11, 2025
Syndax Pharmaceuticals Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript.
Mon Nov 10, 2025
UBS Maintains Syndax Pharmaceuticals (SNDX) Buy Recommendation. Fintel reports that on November 4 2025 UBS maintained coverage of Syndax Pharmaceuticals (NasdaqGS:SNDX) with a Buy recommendation. Analyst Price Forecast Suggests 153.78% Upside
Wed Nov 5, 2025
Barclays Maintains Syndax Pharmaceuticals (SNDX) Overweight Recommendation. Fintel reports that on November 4 2025 Barclays maintained coverage of Syndax Pharmaceuticals (NasdaqGS:SNDX) with a Overweight recommendation. Analyst Price Forecast Suggests 153.78% Upside
Wed Nov 5, 2025
Syndax Pharmaceuticals GAAP EPS of -$0.70 beats by $0.04 revenue of $45.9M misses by $2.07M.
Mon Nov 3, 2025
HC Wainwright & Co. Reiterates Syndax Pharmaceuticals (SNDX) Buy Recommendation. Fintel reports that on October 27 2025 HC Wainwright &. Co. reiterated coverage of Syndax Pharmaceuticals (NasdaqGS:SNDX) with a Buy recommendation. Analyst Price Forecast Suggests 189.62% Upside
Mon Oct 27, 2025
BTIG Reiterates Syndax Pharmaceuticals (SNDX) Buy Recommendation. Fintel reports that on October 27 2025 BTIG reiterated coverage of Syndax Pharmaceuticals (NasdaqGS:SNDX) with a Buy recommendation. Analyst Price Forecast Suggests 189.62% Upside
Mon Oct 27, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
SNDX Stock trends
SNDX Stock performance
SNDX Stock analysis
SNDX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.